The first disclosure of the CCR8 antagonistic antibody, IPG0521, in the Journal of Experimental & Clinical Cancer Research. IPG0521 demonstrates unique cross-reactivity across five species and has shown potent anti-tumor activity. Following successful FDA IND approval, the antibody is now poised to enter Phase I clinical development.
Click here to learn more
pmc.ncbi.nlm.nih.gov/articles/PMC11969927/pdf/13046_2025_Article_3286.pdf
